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lower proportion of females (53.8% vs. 55.7%, respectively; P0.019), and had a
longer mean length of stay (LOS) (13.2 vs. 12.1 days, respectively; P0.001). The
mean cumulative dose was EPO 57,248 Units and DARB 211mcg, resulting in a dose
ratio (Units EPO: mcg DARB) of 271:1. Mean ESA treatment costs were higher for
DARB than for EPO (EPO: $867 vs. DARB: $1,130; P0.001). CONCLUSIONS: In this
analysis of CIA inpatient records, a dose ratio (Units EPO: mcg DARB) of 271:1 was
observed. Mean ESA treatment costs were observed to be approximately 30%
higher for the DARB group than for the EPO group despite a longer LOS for the EPO
group.
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OBJECTIVES: Lung cancer is the leading cause of cancer deaths worldwide (1.38
million cancer deaths, 18.2% of the total) and of cancermorbidity (1.61million new
cases, 12.7% of all new cancers). Currently only three second-line (2L) non-small
cell lung cancer (NSCLC) pharmacotherapies are licensed in the European Union,
the chemotherapies pemetrexed and docetaxel as well as the Epidermal Growth
Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) erlotinib. These therapy
alternatives have shown a comparable efficacy (survival benefit). In the past cost
comparisons showed that erlotinib was less costly compared to docetaxel, which
itself was cheaper than pemetrexed. Nowadays erlotinib (and docetaxel) are still
less expensive than pemetrexed; but docetaxel lost patent protection (basic com-
pound patent) at the end of 2010, so the docetaxel drug costs have decreased
rapidly, which poses the question of whether erlotinib still is the least costly ther-
apy alternative in 2L NSCLC. METHODS: Italy has been selected exemplarily to
compare the total therapy costs, estimated by combining country-specific drug
costs, administration costs and adverse event costs of erlotinib and generic do-
cetaxel in 2LNSCLC therapy. Sensitivity analyses on central input parameters have
been performed. RESULTS: The total costs of treating one patient with erlotinib
therapy of €5121 are lower than the docetaxel costs of €6699 for the Italian health-
care setting. Although the drug costs of erlotinib are higher than generic docetaxel
(incremental €3770), the costs of intravenous chemotherapy administration (incre-
mental -€4510) and the costs of adverse event therapy (incremental -€837) lead to
higher total therapy costs of docetaxel compared to the EGFR TKI therapy erlotinib.
CONCLUSIONS: The cost comparison findings for Italy show that erlotinib is still
the less costly therapy alternative in 2L NSCLC. These results were robust to
changes of central input parameters and robust to further potential price decreases
for docetaxel.
PCN38
PHYSICIAN-SPECIALTY COST DIFFERENCES OF TREATING NON-MELANOMA
SKIN CANCER (NMSC): AN UPDATE
Chirikov VV, Stuart B, Zuckerman IH
University of Maryland School of Pharmacy, Baltimore, MD, USA
OBJECTIVES: Studies have previously reported specialty-related cost differences
for the treatment of non-melanoma skin cancer (NMSC) but without attempting to
establish a causal relationship. This study addresses if specialty-related cost dif-
ferences in the management of NMSC still persist, controlling for potential
confounders.METHODS:Using a previously validatedmodel for episode of care for
NMSC, patients diagnosed with NMSC were identified in part B of the Medicare
Current Beneficiary Survey claims from 2005-07. Physician specialty exposure dur-
ing an episode was defined in three approximately mutually exclusive categories:
1) General Practitioner/Family Medicine/Internal Medicine/General Surgeon/Oth-
ers; 2) Dermatologist; 3) Otolaryngologist/Plastic Surgeon. A log-linear regression
modelwas built of treatment cost as dependent variable and physician exposure as
independent variable controlling for treatment settings, patient demographics,
health status, treatment procedure, tumor size and tumor location that may con-
tribute to differences in the cost of NMSC management. RESULTS: Over years
2005-2007, 1449 unique episodes of care for the management of NMSC were iden-
tified, 24% of which were not treatment-related episodes. Analyzing treatment-
related episodes only, significantmedian cost differences across the three specialty
categories were observed: $297.4 for generalist/other specialist, $441.5 for derma-
tologist, and $672.8 for otolaryngologist/plastic surgeon. In regression analysis,
compared to dermatologist, having seen a generalist/other specialist was associ-
atedwith 29.6% lower costs (P0.001)while having seen an otolaryngologist/plastic
surgeon was associated with 24.6% higher costs (P0.001). Those living in metro
areas were likely to have 11% (P0.04) higher costs. Treating a tumor in the facial
area was associatedwith 17% (P0.001) higher costs than a tumor in the trunk area
of the body.CONCLUSIONS:This study suggests that controlling for demographics,
health status, and treatment predictors, unaccounted specialty-related cost differ-
ences still exist in the management of NMSC and require further investigation.
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OBJECTIVES: To describe the demographic and clinical characteristics and comor-
bidities of colorectal cancer (CRC) patients and to evaluate the disease-specific
expenditures (i.e., insurer-paid costs and patient-incurred out-of-pocket [OOP] ex-
penses) incurred by CRC patients with one, two, and three ormore lines of therapy.
METHODS: Data were from the Thomson Reuters MarketScan® Research Databases.
The analysis population included patients 18 years with incident CRC during
2005-2009who utilized one ormore lines of CRC therapy (defined by a 90-day gap in
treatment or initiation of a new regimen). Demographic characteristics, health
status indices, and comorbidities were measured at baseline and/or during follow-
up. Expenditure data (i.e., paid amounts of adjudicated claims) were collected for
patients while on therapy. OOP expenses were coinsurance and copayments. Av-
erage per-patient monthly expenditures (2009 US dollars) were calculated in com-
posite for all patients from initiation of first-line therapy through follow-up, and
also disaggregated by each line of therapy. RESULTS: Among 13,670 CRC patients,
9,224 (67.5%) had exactly one line of therapy, 2,836 (20.7%) had exactly two lines,
and 1,610 (11.8%) had three ormore lines of therapy. Total per-patient expenditures
for first-line therapy averaged $12,067 per month, but increased to $13,312 for
patients transitioning to second-line therapy, and to $14,651 for patients transi-
tioning to third-line therapy. Monthly OOP expenses were a small (about 2%) con-
tributor to total costs, ranging from $241, $246, and $238 by respective lines of
therapy. Total monthly expenditures for patients covered by commercial insur-
ance were substantially (50%) higher than for patients covered by Medicare sup-
plemental insurance. CONCLUSIONS: Ranging from about $12,000 to $15,000 per
month by increasing lines of therapy, direct costs of CRC present a significant
economic burden to health plans and self-insured employers. Patient-borne OOP
expenses are relatively small but meaningful contributors to the overall financial
burden imposed by CRC.
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OBJECTIVES: To compare survival and healthcare utilization and costs among
Medicare patients with acute myeloid leukemia (AML) versus a matched cohort of
Medicare patients without cancer.METHODS: Patients aged 65 years in the Sur-
veillance, Epidemiology, and End Results (SEER) cancer registry with a new AML
diagnosis from January 1, 1997 to December 31, 2007 were identified (first diagnosis
termed “index”). Patients were required to have 6 months Medicare Part A and B
benefits pre-index and no managed care enrollment post-index. Patients were ex-
cluded if they had another tumor in SEER pre-index. Medicare patients without
cancer were identified and matched up to 5 to 1 based on age (5 years), gender,
race, geographic location, and common comorbidities. Patientswere followed from
index (or index of the corresponding AML patient among controls) to death or
database end (i.e., December 31, 2007). Study measures included median survival
and health care utilization and costs. Generalized linear models were undertaken
to estimate adjusted costs. RESULTS: A total of 6,888 selected AML patients were
matched to 22,346 controls. Among AML patients and controls respectively, mean
(SD) age was 78.3(7.2) and 72.7(6.7) years, median survival was 2.6 and 131.7
months, mean (SD) total follow-up costs were $90,395($104,228) and $26,900
($41,840), and mean (SD) average monthly follow-up costs were $26,990 ($30,719)
and $269 ($468). The largest proportion of costs was hospitalization-related in both
cohorts (74% and 42% of total, respectively). The cost difference between cohorts
was mainly attributable to hospitalizations ($56,314 difference), followed by out-
patient visits ($3,382 difference) (both p0.001). AML patients and controls had
approximately the same number of emergency department, outpatient hospital,
and home health visits. Regression analyses found AML patients accrued $74,177
more in costs than controls (p0.001). CONCLUSIONS: While AML patients had
shorter median survival, they accrued 3 times more costs, mainly driven by hospi-
talizations. This indicates a substantial economic burden incurred by AML patients
to Medicare.
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OBJECTIVES: To estimate costs associated with adverse events (AEs) in patients
receiving targeted therapies for first-line treatment of metastatic renal cell carci-
noma (mRCC).METHODS:A retrospective study utilizing the IntegratedHealthcare
Information Services (IHCIS) claims data from 2000 to 2009 was conducted. Study
subjects were aged 18 years, had mRCC, and received 1st line treatment with
targeted therapies. AEs of interest comprised abdominal pain, back pain, diarrhea,
dyspnea, extremity pain, fatigue/asthenia, hand-foot syndrome, hypertension,
lymphopenia, nausea/vomiting, neutropenia, and proteinuria. Healthcare encoun-
ters for AEs were based on ICD-9-CM diagnosis/procedure codes on healthcare
claims. Costs of AEs were examined over a 30-day period, beginning with the date
of first mention of each AE, and were estimated based on the difference in total
costs between patients with and without events; nonevented patients similarly
were assigned a “shadow” index date. Direct drug costs of targeted agents were
excluded from the analysis. Multivariate generalized linear models (GLM) with a
log-link function and gamma response probability distribution were utilized to
control for differences in baseline characteristics between patients with and with-
out evidence of adverse events. RESULTS: A total of 533 patients were included in
this analysis: 418 patients with adverse events and 115 patients without adverse
events. Baseline characteristics were generally similar between patients in the two
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groups. The GLM-based estimate of the increase in post-event costs over 30 days
among patients with evidence of any adverse events was $9,807 (95% CI: $4,386-
$22,947). For all types of adverse events examined, the estimated difference in costs
between evented andnon-evented patientswas positive; the 95%CI did not include
zero for all of the adverse events considered except hypertension and proteinurea.
CONCLUSIONS: Costs associated with AEs of first-line targeted therapies are sub-
stantial in patients with mRCC. Efforts to prevent and/or better manage these
events may reduce overall healthcare costs.
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OBJECTIVES: To describe patient characteristics and evaluate inpatient utilization
and costs among patients with lung cancer in Tianjin, China. METHODS: Retro-
spective analyses were conducted using Urban Employee Basic Medical Insurance
(UEBMI) claims database from Tianjin from 2003 to 2007, which included a 30%
random sample of UEBMI enrollees in Tianjin. Patients with 1 lung cancer di-
agnosis and continuous eligibility 6 months before and 12 months after the first
diagnosis were selected. Inpatient utilization and costs during the 12-month study
period were estimated. Costs were valued in 2007 US dollars using the correspond-
ing inflation rate and exchange rate. RESULTS: A total of 2351 lung cancer patients
were included with mean age of 66.5 years, 34.9% female, and 86.9% retired. Ap-
proximately 50.0% patients had metastasis at the first diagnosis. Among them,
46.9% had cardiovascular disease, 27.6% had COPD, and 23.3% had hypertension.
The mean number of admissions was 2.44 during the 12 months, with 53.3% of
patients having 1 admission. About 84.8% hospitalizations occurred in a tier-3
hospital. Themean length of stay was 25.9 and 24.2 days, respectively, for first and
subsequent admissions. Anti-neoplastic agents were used in 66.1% hospitaliza-
tions. The mean cost per hospitalization was $2473 and $ 2260 for first and subse-
quent admissions, respectively. The total 12-month inpatient costs were $ 5511 per
patient: 70.9% were covered by payers and the rest by patients. Approximately
58.2% of the total inpatients costs were attributed to medication costs. Examina-
tions,medical consumables and bed accounted for 13.4%, 6.3% and 5.0% of the total
inpatient costs, respectively. CONCLUSIONS: The majority of lung cancer patients
is metastatic and treated in tier-3 hospitals. Lung cancer poses substantial eco-
nomic burden to payers and patients. The majority of the costs were attributed to
medications.
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OBJECTIVES: China has over 50% of new hepatocellular carcinoma (HCC) cases in
the world. The study estimated the economic burden associated with HCC in Tian-
jin, China.METHODS: Data were obtained from the Tianjin Urban Employee Basic
Medical Insurance (UEBMI) database (2003-2007), including inpatient claims for
medical services and prescription drugs for 30% enrollees. Adult patients with  1
diagnosis of HCC and 6-month continuous enrollment before and after the first
HCC diagnosis between 2003 and 2007 were selected. Patient characteristics,
healthcare utilization and costs were analyzed. Costs were estimated in 2007 U.S.
dollars using the Medical Service Consumer Price Index (CPI) in China and an
exchange rate of 7.598 Chinese Yuan to 1 USD in 2007. RESULTS: A total of 857 HCC
eligible patients were included in the analysis with amean age of 62.2 years, 25.0%
female and 72.4% retired. Approximately 65.2% of all patients had 1 comorbidity,
48.4% had cirrhosis, 35.4% had HBV/HCV, 18.1% had esophageal varices, 10.2% had
encephalopathy, and 14.4% had diabetes mellitus. The mean number of hospital-
izations during the 6-month study period was 1.62, with 40.0% patients having 1
hospital admissions. About 84.0% hospitalizations occurred in tier-3 hospitals. The
mean length of stay (LOS) was 24.6 days per hospitalization and 38.9 days during
the 6-month study period. The total 6-month inpatient costs were $4,400 per pa-
tient with 70.1% covered by UEBMI and 29.9% by patients. Medication costs ac-
counted for 56.3% of total inpatient costs; the rest was attributed to medical ser-
vices. Examinations,medical consumables and bed costs accounted for 14.3%, 9.3%
and 4.9% of total inpatient costs, respectively. CONCLUSIONS: The majority of
Chinese HCC patients receive treatment in tier-3 hospitals. HCC poses substantial
economic burden to the payer and patients in China. Medications accounts for
more than half of the total inpatient costs.
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OBJECTIVES: Chemotherapy-induced nausea and vomiting (CINV) is a major ad-
verse effect of cancer treatment. The 5-hydroxytryptamine3 receptor antagonists
(5-HT3-RA), a class of antiemetic medications, are indicated for the prevention of
CINV. This study compared treatment costs of patients with and without CINV
following a highly or moderately emetogenic chemotherapy regimen and anti-
emetic prevention with a 5-HT3-RA. METHODS: This study was a retrospective
cohort analysis using the MarketScan® Medicaid database. Continuously enrolled
adult patients, newly diagnosed with cancer, newly treated with a MEC or HEC
regimen, who received a prophylactic 5-HT3-RA during the January 1, 2005 to De-
cember 31, 2009, were identified. The primary outcome of interest was the overall
cost of care for patients with and without CINV. CINV was defined by any claim for
nausea and vomiting, fluid depletion or replacement, and the use of a rescue anti-
emetic during a cycle of chemotherapy. RESULTS: A total of 8812 patients were
identified, 33%undergoingHEC and 67% treatedwith aMEC regimen. Themean age
was 56.7 and 65%were female. Patients were treated with a total of 43,418 cycles of
chemotherapy. The overall rate of CINV was 17% per cycle and the rate differed by
prophylactic 5-HT3-RA utilized. The rate of CINV per cycle for patients treated with
palonosetron was 13% compared to 20% for those treated with another 5-HT3-RA.
The average total paid health care cost per cycle was $2827. Average cost per cycle
with and without CINV was $3839 and $2695, respectively, p0.001.
CONCLUSIONS: In this retrospective study, health care costs associated with the
prevention of CINV were approximately $1144 per cycle of chemotherapy. This
suggests that a reduction in the rate of CINV for patients undergoing chemotherapy
could result in significant health care cost savings in the Medicaid system. Further
studies are warranted to confirm these findings.
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OBJECTIVES: Melanoma is the most serious type of skin cancer that starts in me-
lanocytes. New treatment methods may offer significant benefits in treating pa-
tients with advanced melanoma, but in order to assess their cost-effectiveness via
pharmacoeconomic modelling data on epidemiology, current standard of care,
adverse events and costs is needed. The aim of this study is to collect such infor-
mation using surveys in major centers in Poland.METHODS: A questionnaire was
designed and implemented in MS Excel, and then distributed in three hospitals in
Poland covering the majority of melanoma patients being treated. The survey
questions encompassed: the disease characteristics, current treatment patterns,
health care resources utilization and costs among patients diagnosed with mela-
noma (SIII-SIV). Resources costs and standard of care data for melanoma patients
were divided into three therapy lines, and information such as treatment scheme,
drug cost and performed diagnostic procedures were collected. RESULTS: The pre-
liminary results coming from one center are available at this stage. Melanoma
incidence andmortality rate (per 100,000) are equal respectively to 8.8 and 3.7 (data
for year 2010). The continuation of existing trends will cause an increase of mor-
bidity in the next years and the numer of incidence cases can even double in 10
years time. The most common form of treatment in metastatic patients is chemo-
therapy. The results demonstrate that costs of consecutive lines of therapy de-
crease, and total yearly cost of 1st, 2nd and 3rd line treatment is estimated to be
1.2mln PLN (1 Euro4.4 PLN). Adverse events total cost amounts to 77,000 PLN.
CONCLUSIONS:Melanoma is one of the most malignant human cancers in Poland
with an increasing incidence rate. In connection with several treatment patterns
that exist, it is necessary to gather detailed clinical data in order to use it in phar-
macoeconomic modelling in health technology assessment process.
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OBJECTIVES: To assess the clinical and economic burden of ovarian cancer in the
US veteran population.METHODS: A retrospective study (October 01, 2005 to Sep-
tember 30, 2010) was conducted using the Veterans Health Affairs Medical SAS
Datasets. Patients diagnosed with ovarian cancer were included in the study.
Health care resource utilization and costs were assessed for ovarian cancer pa-
tients in the 12-month follow-up period. Patients’ demographic, clinical and dis-
charge statuses were compared using Chi-square testing and standardized differ-
ences. Student t-tests were used for the means of continuous variables. Mortality
and survival rateswere also calculated using the Kaplan andMeiermethod and the
PROC LIFETEST procedure. RESULTS: Among the selected ovarian cancer patients
(n1,148), the total mortality rate in the 12-month follow-up period was 20.84%
(n239). The most commonly prescribed medications were sodium chloride
(3.14%), dextrose (1.83%), potassium chloride (1.58%), and warfarin (1.02%). The
average number of inpatient (0.46), emergency room (ER) (0.41), physician office
(30.31) and outpatient visits (30.74) were calculated per patient. The percentage of
inpatient, ER, physician office and outpatient were 27.35%, 21.43%, 100% and 100%,
respectively. The cost of inpatient, ER, physician office and outpatient visits were
$6610, $138, $9702, and $9959, respectively. CONCLUSIONS: More research is re-
quired to better understand adverse events and side effects of ovarian cancer treat-
ments. This study suggests that sodium chloride and dextrose were the most fre-
quently prescribed drugs after diagnosis of ovarian cancer.
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